Blood Pressure Disorders Drug Development Pipeline Review 2018 - Molecule Type, Molecular Target, Mechanism of Action and Route of Administration

DUBLIN, Sept. 17, 2018 /PRNewswire/ --

The "Blood Pressure Disorders Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

This report Blood Pressure Disorders Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for blood pressure disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for hypertension, pulmonary arterial hypertension (PAH) and hypotension, and features dormant and discontinued products.

Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in the body and the condition of the kidneys, nervous system, and blood vessels.

Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically do not occur until high blood pressure has reached a severe stage. There are 253 products in development for this indication.

PAH is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). There are 92 products in development for this indication.

Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Pipeline activity is much lower for hypotension than for hypertension or PAH with only seven products in development for this indication.

Molecular targets acted on by products in development for blood pressure disorders include angiotensin receptors, tyrosine protein kinases and phosphodiesterases.

Scope

• Which companies are the most active within the pipeline for blood pressure disorders?
• Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Key Topics Covered:

1 Tables & Figures

2 Introduction

2.1 Blood Pressure Disorder Report Coverage
2.2 Hypertension - Overview
2.3 Hypotension - Overview
2.4 Pulmonary Arterial Hypertension - Overview

3 Therapeutics Development

3.1 Hypertension
3.2 Hypotension
3.3 Pulmonary Arterial Hypertension

4 Therapeutics Assessment

4.1 Hypertension
4.2 Hypotension
4.3 Pulmonary Arterial Hypertension

5 Companies Involved in Therapeutics Development

5.1 Hypertension
5.2 Hypotension
5.3 Pulmonary Arterial Hypertension

6 Dormant Projects

6.1 Hypertension
6.2 Hypotension
6.3 Pulmonary Arterial Hypertension

7 Discontinued Products

7.1 Hypertension
7.2 Pulmonary Arterial Hypertension

8 Product Development Milestones

8.1 Hypertension
8.2 Hypotension
8.3 Pulmonary Arterial Hypertension

Companies Mentioned

• A1M Pharma AB
• Acceleron Pharma Inc
• Ache Laboratorios Farmaceuticos SA
• Actelion Pharmaceuticals Ltd
• Aerogen Ltd
• Anavex Life Sciences Corp
• AnGes Inc
• Arena Pharmaceuticals Inc
• Ascendia Pharmaceuticals LLC
• Ascendis Pharma A/S
• AVEO Pharmaceuticals Inc
• Bayer AG
• BCO Pharma Ltd
• Bial - Portela & Ca SA
• Bioblue Technologies Inc
• Biogen Inc
• Biolab Farmaceutica Ltda
• BioRestorative Therapies Inc
• Boryung Pharmaceutical Co Ltd
• Bristol-Myers Squibb Co
• Camurus AB
• Capricor Therapeutics Inc
• Celsion Corp
• Celtaxsys Inc
• Cerecor Inc
• Chiesi Farmaceutici SpA
• Chong Kun Dang Pharmaceutical Corp
• Chugai Pharmaceutical Co Ltd
• CJ HealthCare Corp
• Complexa Inc
• Corion Biotech Srl
• Cumberland Pharmaceuticals Inc
• D. Western Therapeutics Institute Inc
• Daewon Pharm Co Ltd
• Daewoong Co Ltd
• Daewoong Pharmaceutical Co Ltd
• Daiichi Sankyo Co Ltd
• Denovo Biopharma LLC
• Eli Lilly and Co
• Esperion Therapeutics Inc
• FunPep Co Ltd
• Galectin Therapeutics Inc
• Gemphire Therapeutics Inc
• Gilead Sciences Inc
• GlaxoSmithKline Plc
• H. Lundbeck AS
• HanAll Biopharma Co Ltd
• Hanmi Pharmaceuticals Co Ltd
• Hypotension
• Idorsia Pharmaceutical Ltd
• Ildong Pharmaceutical Co Ltd
• Innopharmax Inc
• Insmed Inc
• Insys Therapeutics Inc
• Ionis Pharmaceuticals Inc
• Japan Tobacco Inc
• Jeil Pharmaceutical Co Ltd
• Johnson & Johnson
• KBP BioSciences Co Ltd
• La Jolla Pharmaceutical Company
• Leading BioSciences Inc
• Lee's Pharmaceutical Holdings Ltd
• Les Laboratoires Servier SAS
• LG Chem Ltd
• LinXis BV
• Liquidia Technologies Inc
• MannKind Corp
• Marina Biotech Inc
• Merck & Co Inc
• Mezzion Pharma Co Ltd
• N4 Pharma Plc
• Nippon Shinyaku Co Ltd
• Nissan Chemical Industries Ltd
• Northern Therapeutics Inc
• Novartis AG
• Omeros Corp
• Orion Corporation
• Peloton Therapeutics Inc
• Pfizer Inc
• PhaseBio Pharmaceuticals Inc
• Pulmokine Inc
• Pulmonary Arterial Hypertension
• Quantum Genomics SA
• Reata Pharmaceuticals Inc
• Relief Therapeutics Holding AG
• Relypsa Inc
• Renova Therapeutics Inc
• Respira Therapeutics Inc
• Reviva Pharmaceuticals Inc
• rEVO Biologics Inc
• Roivant Sciences Ltd
• Rottapharm Biotech Srl
• Sanofi
• Sarfez Pharmaceuticals Inc
• Serodus ASA
• Shanghai Pharmaceutical Co Ltd
• SJT Molecular Research SL
• SteadyMed Therapeutics Inc
• Suda Pharmaceuticals Ltd
• Sumitomo Dainippon Pharma Co Ltd
• Sun Pharma Advanced Research Company Ltd
• Takeda Pharmaceutical Co Ltd
• Target Medicals LLC
• The Medicines Company
• Theracos Inc
• Theravance Biopharma Inc
• Toray Industries Inc
• TrioxBio Inc
• United Therapeutics Corp
• Vascular BioSciences
• VG Life Sciences Inc
• Vicore Pharma AB
• Vivus Inc
• XuanZhu Pharma Co Ltd
• Yuhan Corp

For more information about this report visit https://www.researchandmarkets.com/research/mnzckt/blood_pressure?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com